Next Technology's 15min chart sees KDJ Golden Cross, Bullish Marubozu Candlestick Pattern

Based on Next Technology's 15-minute chart, a significant technical indicator has been triggered, namely the KDJ Golden Cross, which occurred on October 7th, 2025 at 12:00. This bullish signal suggests that the momentum of the stock price is shifting towards the upside, indicating potential for further growth. The presence of a Bullish Marubozu candlestick pattern further reinforces this bullish sentiment, as it signifies strong buying pressure and control of the market. Consequently, it is likely that the bullish momentum will continue, and investors should consider buying the stock with caution.

On October 7, 2025, Sonoma Pharmaceuticals (SNOA) experienced a significant technical indicator trigger, the KDJ Golden Cross, at 12:00 PM. This bullish signal suggests a shift in the stock's momentum towards the upside, indicating potential for further growth. The presence of a Bullish Marubozu candlestick pattern reinforces this sentiment, indicating strong buying pressure and market control Sonoma Pharmaceu Stock Price, News & Analysis^[1].

Sonoma Pharmaceuticals, a healthcare company specializing in Microcyn® technology-based stabilized hypochlorous acid (HOCl) products, has been making notable strides in the market. On the same day, the company announced the registration of its manufacturing facility and a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act (MoCRA). This move expands the company's regulatory footprint and positions it to tap into the U.S. cosmetics and dermatology consumer markets, which are projected to reach $40 billion by 2030 .

The company's recent financial performance has been robust. In its Q1 FY2026 financial results, Sonoma Pharmaceuticals reported total revenue of $4.0 million, an 18% increase year-over-year. The company achieved strong performance in key markets, with U.S. revenue surging 57% and European revenue growing 14%. Despite a net loss of $1.2 million, the company held cash reserves of $3.6 million as of June 30, 2025 .

Moreover, Sonoma Pharmaceuticals has been actively participating in industry events and conferences. The company announced its participation in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, where management will be available for one-on-one meetings with investors .

In conclusion, the combination of the KDJ Golden Cross, Bullish Marubozu candlestick pattern, and recent regulatory and financial achievements suggests that Sonoma Pharmaceuticals (SNOA) is poised for further growth. Investors should consider the stock with caution, keeping an eye on the company's ongoing strategic initiatives and market performance.